News
Press releases
Pharnext in discussions with investment research firm Edison to update valuation of assets
January 5, 2023
Pharnext strengthens its Senior Leadership Team with the appointment of Scott Johnson as VP, Head of Quality
January 4, 2023
Pharnext strengthens its ties with Néovacs to secure the next steps in its development
December 28, 2022
The Board of Directors of Pharnext acknowledges the resignation of Dr. David Horn SOLOMON from his duties as Chief Executive Officer and Director of the Company
November 28, 2022
Pharnext announces the completion of the reverse split of its shares on the basis of 1 new share for 5,000 old shares, the start of trading of the shares resulting from the reverse split as of Wednesday 23 November 2022, and a reduction of its share capital
November 22, 2022
Hugo Brugière Joins Pharnext Board of Directors
November 8, 2022
Pharnext announces that Neovacs has set-up a management trust to manage the Pharnext securities issued and the rights and obligations of Neovacs under the financing agreement signed on September 30th, 2022
October 31, 2022
Pharnext Reports First Half 2022 Financial Results
October 17, 2022
Pharnext executes a financing agreement with Néovacs for EUR 20.7 million net to further develop PXT3003 for Charcot-Marie-Tooth disease type 1A
October 3, 2022
Pharnext announces a reverse stock split and suspension of the right to exercise all the securities giving access to Pharnext's share capital including the conversions of convertible bonds
October 3, 2022
Contact
˪ For media
Pharnext Headquarters
Financial Press Relation (France)